This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
by Zacks Equity Research
Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $109.46, representing a -0.65% change from its previous close.
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
by Zacks Equity Research
Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.
Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?
by Sanghamitra Saha
Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Company News for Jan 3, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, RCL, NVDA, MRK
Why the Market Dipped But Moderna (MRNA) Gained Today
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.
Stock Market News for Dec 28, 2023
by Zacks Equity Research
Wall Street closed higher on Wednesday, with the S&P 500, the Dow and the Nasdaq notching their longest winning streak since 2017.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
by Zacks Equity Research
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
by Zacks Equity Research
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
by Kinjel Shah
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.
Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy
by Zacks Equity Research
The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.
Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
by Zacks Equity Research
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
by Zacks Equity Research
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
by Zacks Equity Research
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.